Human Umbilical Cord Mesenchymal Stromal Cells Therapy for Neuromyelitis Optica Spectrum Disorder: a phase 1/2a trial
This study aimed to evaluate the safety and efficacy of human umbilical cord-derived mesenchymal stromal cells (hUC-MSCs) in preventing relapses and alleviating neurological impairment in patients with neuromyelitis optica spectrum disorder (NMOSD). Despite existing therapies focusing on relapse management, residual neurological dysfunction remains a significant unmet need.